Ocugen rises on promising data for COVID-19 vaccine candidate

Hanall Biopharma

15/12/2021 12:36

(Repeats to fix formatting in second-last bullet)
    ** Shares of biopharma co  OCGN.O  up ~8% at $5.21 premarket
    ** A third-party study shows co's vaccine candidate,
Covaxin, to generate a robust immune memory to COVID-19 and
variants of concern for at least six months after vaccination
 urn:newsml:reuters.com:*:nGNX5rc57z 
    ** Immune memory is the ability of the immune system to
respond more rapidly and effectively to pathogens that have been
encountered previously
    ** "In addition to controlling infections, the adaptive
immune system creates immunological memory, such as memory B and
T cells, to enable long-term protection against a virus" – co
    ** OCGN is currently testing Covaxin against the Omicron
variant and plans to share the data as soon as they are
available
    ** Last month, U.S. FDA issued clinical hold on its
application seeking clearance to begin clinical trial of Covaxin
 urn:newsml:reuters.com:*:nL4N2SH2ZC 
    ** The vaccine has been approved for emergency use by the
World Health Organization  urn:newsml:reuters.com:*:nL1N2RU107
    ** Up to Tuesday's close, stock had risen 162.84% YTD

 (Reporting by Oishee Majumdar in Bengaluru)
 ((oishee.majumdar@thomsonreuters.com;))